Study Summary
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Want to learn more about this trial?
Request More InfoInterventions
FludarabineDRUG
Received IV on Days -5 to -3 before CAR T cell therapy
CyclophosphamideDRUG
Received IV on Days -5 to -3 before CAR T cell therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Caitlin Guzowski | Atlanta | Georgia | United States |